Bringing genomics to the bedside: a cost-effective pharmacogenomic test?
Veenstra
David L
DL
School of Pharmacy, University of California, San Francisco, California 94143, USA. davidv@itsa.ucsf.edu
D003362:Cost-Benefit Analysis; D015224:Dideoxynucleosides / Q000191:economics; D005838:Genotype; D015235:HLA-B Antigens / Q000191:economics / Q000235:genetics; D006801:Humans; D025202:Molecular Diagnostic Techniques / Q000191:economics*; D010597:Pharmacogenetics / Q000191:economics*; D019095:Point-of-Care Systems / Q000191:economics*; D018894:Reverse Transcriptase Inhibitors / Q000191:economics; D000099227:Abacavir
D015224:Dideoxynucleosides; D015235:HLA-B Antigens; D018894:Reverse Transcriptase Inhibitors; D000099227:Abacavir; C484830:HLA-B*57:01 antigen